Table 2.
Median and interquartile range (Q1–Q3) of different parameters at different follow-up time in mCNV patients.
| T0 | T1 | T2 | p-value a | |
|---|---|---|---|---|
| BCVA (logMAR) | 0.6 (0.5–0.8) | 0.3 (0.3–0.4)* | 0.3 (0.3–0.4) | < 0.001 |
| FA Leakage | 2 (2–2) | — | 0 (0–0.3) | 0.003 b |
| FA area (mm2) | 0.8 (0.5–3) | — | 0.5 (0.3–1.5) | 0.005 b |
| OCTA Selected Area (mm2) | 0.9 (0.5–2.9) | 0.6 (0.3–2)* | 0.5 (0.2–1.5) | 0.005 |
| OCTA Flow Area (mm2) | 0.5 (0.3–1.5) | 0.3 (0.2–0.9)* | 0.3 (0.1–0.6) | 0.013 |
| CRT (µm) | 387.5 (331.0–435.8) | 285.0 (257.5–333.5)* | 267.0 (255.3–314.5) | < 0.001 |
| ELM visualization | 0 (0–0) | 2 (1.7–2)* | 2 (1.8–2) | < 0.001 |
| PlGF (pg/ml) | 1.8 (1.5–2.9) | 1.4 (1.1–1.9)* | — | 0.019 b |
| VEGF (pg/ml) | 3.4 (2–5.6) | 0.5 (0.1–0.9)* | — | 0.008 b |
BCVA, best corrected visual acuity; FA, fluorescein angiography; OCTA, optical coherence tomography angiography; CRT, central retinal thickness; ELM, external limiting membrane; PlGF, placental growth factor; VEGF, vascular endothelial growth factor.
aFriedman test; bWilcoxon U test.
*p < 0.05 post hoc analysis respect to previous follow-up control.